UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-KSB

[X]      ANNUAL  REPORT  PURSUANT  TO  SECTION  13 OR  15(d)  OF THE  SECURITIES
         EXCHANGE ACT OF 1934

         For the fiscal Year ended:    December 31, 2000
                                    -------------------------

                                       OR

[]       TRANSITION  REPORT  PURSUANT  TO SECTION 13 OR 15(d) OF THE  SECURITIES
         EXCHANGE ACT OF 1934

For the transition period from                       to
                               ---------------------    -----------------------

Commission file number    33-55254-09
                       -----------------

                        ROCKY POINT PHARMACEUTICALS, INC.

           NEVADA                                         87-0434293
--------------------------------             -----------------------------------
(State or other jurisdiction of              (I.R.S. Employer Identification
incorporation or organization)                        Number.)

 2601 Quincy, Ogden, UTAH                              84401
----------------------------------------            ----------
(Address of principal executive offices)            (Zip Code)

Issuer's telephone number, including area code    (801) 424-2424
                                               ------------------

50 West Broadway, Suite 1111
Salt Lake City, Utah 84101           (801) 363-1600
---------------------------------------------------
(Former Address and Telephone Number)

Securities registered pursuant to Section 12(b) of the Act:   NONE

Securities registered pursuant to Section 12(g) of the Act:   NONE

         Indicate  by check mark  whether  the issuer (1) has filed all  reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.
 [X] Yes   [  ] No

         Indicate by check mark if disclosure of delinquent  filers  pursuant to
Item 405 of  Regulations  S-K  (ss.229.405  of this  chapter)  is not  contained
herein,  and will not be contained,  to the best of registrant's  knowledge,  in
definitive proxy or information statements incorporated by reference in Part III
of this Form 10-KSB or any amendment to this Form 10-KSB. [X]

         As of March 20, 2001,  there is no aggregate market value of the voting
stock held by non-affiliates of the registrant.

         Indicate the number of shares  outstanding of each of the  registrant's
classes of common stock, as of the latest practicable date.

         Class                               Outstanding as of December 31, 2000
------------------------------------         -----------------------------------
$.001 PAR VALUE CLASS A COMMON STOCK            1,000,000 SHARES

                    DOCUMENTS INCORPORATED BY REFERENCE: NONE


<PAGE>



ITEM 1.           Business

         The  company  was  incorporated  under the laws of the State of Utah on
April 14, 1986 and  subsequently  reincorporated  under the laws of the State of
Nevada on  December  30,  1993,  and is in the  development  stage.  The Company
intends to begin the process of investigating  potential business ventures which
in the opinion of  management,  will provide a source of eventual  profit to the
Company.  Such involvement may take many forms,  including the acquisition of an
existing  business  or  the  acquisition  of  assets  to  establish   subsidiary
businesses.  The  Company's  management  does not expect to remain  involved  as
management of an acquired business;  presently unidentified individuals would be
retained for such purposes.

         As an unfunded  venture,  the Company will be extremely  limited in its
attempts to locate potential business situations for investigation. However, the
Company's  officers,  directors and major  shareholder  have  undertaken to make
loans to the Company in amounts sufficient to enable it to satisfy its reporting
and other obligations as a public company, and to commence,  on a limited basis,
the process of  investigating  possible merger and acquisition  candidates,  and
believe that the Company's  status as a publicly-held  corporation  will enhance
its ability to locate such potential business ventures.

         No  assurance  can be given as to when the Company may locate  suitable
business  opportunities and such  opportunities may be difficult to locate.  The
Company intends not to allocate any incoming funds specifically, should there be
any in the future, to general use for the purpose of seeking,  investigating and
acquiring or becoming engaged in a business  opportunity.  Decisions  concerning
these  matters  may  be  made  by  management   without  the   participation  or
authorization of the shareholders.

         Management  anticipates  that due to its lack of funds, and the limited
amount of its resources,  the Company may be restricted to participation in only
one  potential  business  venture.  This  lack  of  diversification   should  be
considered a  substantial  risk because it will not permit the Company to offset
potential losses from one venture against gains from another.

         Business opportunities,  if any arise, are expected to become available
to the  Company  principally  from the  personal  contacts of its  officers  and
directors.  While it is not expected  that the Company will engage  professional
firms specializing in business  acquisitions or reorganizations,  such firms may
be  retained  if funds  become  available  in the  future,  and if  deemed to be
advisable.  Opportunities may thus become available from professional  advisers,
securities  broker-dealers,   venture  capitalists,  members  of  the  financial
community, and other sources of unsolicited proposals. In certain circumstances,
the  Company  may agree to pay a  finder's  fee or other  form of  compensation,
including  perhaps  one-time cash payments,  payments based upon a percentage of
revenues or sales volume,  and/or payments involving the issuance of securities,
for services provided by persons who submit a business  opportunity in which the
Company shall decide to  participate,  although no contracts or  arrangements of
this nature  presently  exist. The Company is unable to predict at this time the
costs of locating a suitable business opportunity.

         The Company will not restrict  its search to any  particular  business,
industry or  geographical  location,  and  reserves the right to evaluate and to
enter into any type of business  opportunity,  in any stage of their development
(including the upstart stages) in any location.  In seeking  business  ventures,
management  can not be influenced  primarily by an attempt to take  advantage of
the anticipated or perceived appeal in specific  industry,  management group, or
product or  industry,  but rather will be motivated  by the  Company's  business
objective  of seeking  long term capital  appreciation  in their real value.  In
addition, the Exchange Act reporting requirements require the filing of the Form
8-K disclosing any businesses acquired and requires audited financial statements
of such companies.  These reporting  requirements  may  substantially  limit the
businesses which may be available for possible acquisition candidates.

         The analysis of business  opportunities  will be undertaken by or under
the  supervision  of the Company's  management,  none of whom is a  professional
analyst and none of whom have significant general business experience. Among the
factors  which  management  will  consider  in  analyzing   potential   business
opportunities are the available technical,  financial and managerial  resources:
working capital and financial  requirements;  the history of operation,  if any;
future prospects; the nature of present and anticipated  competition;  potential
for  further  research,   development  or  exploration;   growth  and  expansion
potential;  profit potential;  the perceived public recognition or acceptance of
products or services; name identification, and other relevant factors.


                                        2

<PAGE>



         It is not  possible at present to predict the exact manner in which the
Company  may   participate  in  a  business   opportunity.   Specific   business
opportunities  will be reviewed  and,  based upon such review,  the  appropriate
legal structure or method of  participation  will be decided upon by management.
Such structures and methods may include,  without limitation,  leases,  purchase
and  sale  agreements,   license,   joint  ventures;  and  may  involve  merger,
consolidation  or  reorganization.  The Company may act  directly or  indirectly
through an interest in a partnership, corporation or reorganization. The Company
may act directly or indirectly through an interest in a partnership, corporation
or other form or organization.  However, it is most likely that the Company will
acquire a business venture by conducting a reorganization involving the issuance
of the Company's  restricted  securities.  Such a  reorganization  may involve a
merger (or combination  pursuant to state corporate  statutes,  where one of the
entities  dissolves  or is  absorbed  by  the  other),  or  it  may  occur  as a
consolidation,  where a new  entity is formed  and the  Company  and such  other
entity  combine  assets in the new  entity.  A  reorganization  may also  occur,
directly or indirectly, through subsidiaries, and there is no assurance that the
Company would be the surviving entity. Any such  reorganization  could result in
additional  dilution  to the book  value of the  shares and loss of control of a
majority of the  shares.  The  Company's  present  directors  may be required to
resign in connection with a reorganization.

         A  reorganization  may be structured in such a way as to take advantage
of certain beneficial tax consequences available in business reorganizations, in
accordance  with  provisions of the Internal  Revenue Code of 1986 (as amended).
Pursuant  to  such  a  structure,  the  number  of  shares  held  prior  to  the
reorganization  by all of the Company's  shareholders  might be less than 20% of
the  total  shares  to  be  outstanding  upon  completion  of  the  transaction.
Substantial  dilution of percentage  equity ownership may result to the minority
shareholders, in the discretion of management.

         Generally,  the issuance of securities in a reorganization  transaction
would  be  undertaken  in  reliance  upon  one  or  more   exemptions  from  the
registration  provisions of applicable  federal  securities laws,  including the
exemptions  provided  for  non-public  or limited  offerings,  distributions  to
persons resident in only one state and similar exemptions provided by state law.
Shares issued in a reorganization  transaction based upon these exemptions would
be  considered  "restricted"  securities  under the 1933  Act,  and would not be
available  for  resale  for a period of one year,  in  accordance  with Rule 144
promulgated  under  the 1933 Act.  However,  the  Company  might  undertake,  in
consideration  with  such  a  reorganization  transaction  certain  registration
options in connection with such securities.

         The  Company  may  choose  to  enter  into  a  venture   involving  the
acquisition  of or  merger  with a  company  which  does  not  need  substantial
additional  capital but desires to establish a public  trading  market for their
securities.  Such a company may desire to consolidate  its  operations  with the
Company  through  a  merger,   reorganization,   asset  acquisition,   or  other
combination,  in order to avoid possible adverse consequences of undertaking its
own public offering. (Such consequences might include expense, time delays, loss
of voting control and the necessity of complying with various  federal and state
laws enacted for the  protection of  investors.)  In the event of such a merger,
the Company may be required to issue significant  additional  shares, and it may
be  anticipated  that control over the Company's  affairs may be  transferred to
others.  It should also be noted that this type of business  venture  might have
the effect of depriving the minority shareholders of the purported protection of
federal  and state  securities  laws,  which  normally  affect the  process of a
company's becoming publicly held.

         It  is  likely  that  the   investigation  and  selection  of  business
opportunities  will be complex,  time-consuming  and extremely  risky.  However,
management believes that even though the Company will have limited capital,  the
fact that  their  securities  will be  publicly-held  will make it a  reasonably
attractive business prospect for other firms.

         As  part of  their  investigation  of  acquisition  possibilities,  the
Company's  management may meet with  executive  officers of the business and its
personnel;  inspect its facilities;  obtain independent analysis or verification
of the  information  provided,  and conduct other  reasonable  measures,  to the
extent permitted by the Company's  limited  resources and  management's  limited
expertise.  Generally,  the Company  intends to analyze and make a determination
based upon all available  information without reliance upon any single factor as
controlling.

         In all likelihood,  the Company's  management will be  inexperienced in
the areas in which potential  businesses  will be investigated  and in which the
Company may make an acquisition or investment. Thus, it may become necessary for
the  Company  to retain  consultants  or  outside  professional  firms to assist
management in evaluating potential  investments,  and to hire managers to run or
oversee the operations of its acquisitions or investments.  The Company can give
no assurance that it will be able to find suitable consultants or managers.  The
Company intends not to employ any of its

                                        3

<PAGE>



affiliates,  officers,  directors or principal shareholders as consultants.  The
Company has no policy regarding the use of consultants,  however, if management,
in its  discretion,  determines that it is in the best interests of the Company,
management  may seek  consultants  to review  potential  merger  or  acquisition
candidates.  It is  anticipated  that  the  total  amount  of  fees  paid to any
consultant would not exceed $5,000 per transaction.  The fee, it is anticipated,
would be paid by the potential target company.  There are currently no contracts
or agreements  between any  consultant  and any companies that are searching for
"shell"  companies  with  which  to  merge.   There  have  been  no  preliminary
discussions or understandings between the Company and any market maker regarding
the  participation of any such market maker in the aftermarket for the Company's
securities  inasmuch as no market for the securities is expected to arise due to
the lack of transferability on the Company's shares until an acquisition is made
and a Form 8-K is filed with the Commission.

         It may be  anticipated  that the  investigation  of  specific  business
opportunities  and the  negotiation  time and execution of relevant  agreements,
disclosure  documents and other instruments will require substantial  management
time and attention, and substantial costs of accountants,  attorneys and others.
Should a decision  thereafter be made not to participate in a specific  business
opportunity,  it is likely that costs already expended would not be recoverable.
It is also  likely,  in the event a  transaction  should  eventually  fail to be
consummated, for any reason, that the costs incurred by the Company would not be
recoverable.  The Company's officers and directors are entitled to reimbursement
for all expenses  incurred in their  investigation of possible business ventures
on behalf of the Company,  and no assurance can be given that if the Company has
available funds they will not be depleted in such expenses.

         In addition to the severe limitations placed upon the Company by virtue
of its unfunded status,  the Company will also be limited,  in its investigation
of  possible  acquisitions,  by the  reporting  requirements  of the  Securities
Exchange Act of 1934, pursuant to which certain information must be furnished in
connection with any significant  acquisitions.  The Company would be required to
furnish,  with  respect  to  any  significant  acquisition,   audited  financial
statements for the acquired company, covering one, two or three years (depending
upon the relative size of the acquisition).  Consequently, acquisition prospects
which do not have the requisite audited financial  statements,  or are unable to
obtain them, may be inappropriate  for acquisition  under the present  reporting
requirements of the 1934 Act.

         The Company does not intend to take any action which would render it an
investment company under The Investment  Companies Act of 1940 (the "1940 Act").
The 1940 Act defines an investment  company as one which (1) invests,  reinvests
or  trades  in  securities  as its  primary  business,  (2)  issues  face-amount
certificates of the installment type or (3) invests,  reinvests,  owns, holds or
trades  securities  or owns or  acquires  investment  securities  having a value
exceeding 40 percent of the value of its total assets  (exclusive  of Government
securities  and cash  items) on an  unconsolidated  basis.  The above 40 percent
limitation may be exceeded so long as a company is primarily  engaged,  directly
or through wholly- owned  subsidiaries,  in a business or businesses  other than
that of investing,  reinvesting,  owning,  holding or trading in  securities.  A
wholly-owned  subsidiary  is  defined  as one which is at least 95% owned by the
company.

         Neither the Company nor any of its officers or directors are registered
as investment  advisers under the Investment Advisers Act of 1940 (the "Advisers
Act"),  and so there is no  authority  to  pursue  any  course  of  business  or
activities  which  would  render  the  Company  or  its  management  "investment
advisers" as defined in the Advisers Act.  Management believes that registration
under  the  Advisers  Act  is not  required  and  that  certain  exemptions  are
available,  including  the  exemptions  for persons  who may render  advice to a
limited number of other persons and who may advise other persons  located in one
state only.

         The Company expects to encounter intense  competition in its efforts to
locate  suitable  business   opportunities  in  which  to  engage.  The  primary
competition  for  desirable  investments  may come from  other  small  companies
organized  and funded for  similar  purposes,  from small  business  development
corporations and from public and private venture capital  organizations.  As the
Company  will be  completely  unfunded,  it can  fairly  be said that all of the
competing  entities  will  have  significantly  greater  experience,  resources,
facilities,  contacts  and  managerial  expertise  than the  Company  and  will,
consequently,  be in a better position than the Company to obtain access to, and
to engage in, business opportunities.  Due to the lack of funds, the Company may
not be in a position to compete  with larger and more  experienced  entities for
business  opportunities  which are low-risk.  Business  opportunity in which the
Company may ultimately  participate  are likely to be highly risky and extremely
speculative.


                                        4

<PAGE>



ITEM 2.           Properties.

         The Company owns no properties and utilizes space on a rent-free basis.
This  arrangement is expected to continue until such time as the Company becomes
involved in a business venture which necessitates its relocation, as to which no
assurances  can be given.  The Company  has no  agreements  with  respect to the
maintenance or future acquisition of office facilities, however, if a successful
merger/acquisition  is  negotiated,  it is  anticipated  that the  office of the
Company will be moved to that of the acquired company.

ITEM 3.           Legal Proceedings.

         Other than the matter  discussed in Form 10-K,  dated  December,  1994,
which was settled on September,  1994, no legal  proceedings  have been filed or
are expected to be filed against the Company.

ITEM 4.           Submission of Matters to a Vote of Security Holders.

         No matter was  submitted to the Company's  security  holders for a vote
during the fourth quarter of the fiscal year ending December 31, 2000.

                                     PART II

ITEM 5.           Market for Registrant's Common Equity and Related Stockholders
                  Matters.

         There  currently is not a trading  market for the  Company's  $.001 par
value common stock nor has there been a trading  market for the Company's  stock
since its inception.

         As of December 31, 2000, there were 749 record holders of the Company's
common stock.  The Company has not previously  declared or paid any dividends on
its  common  stock  and does  not  anticipate  declaring  any  dividends  in the
foreseeable future.

ITEM 6.           Management's Discussion and Analysis or Plan of Operation.

         The  Company  has had no  operational  history and has yet to engage in
business of any kind.  All risks inherent in new and  inexperienced  enterprises
are inherent in the Company's business.  The Company has not made a formal study
of the economic  potential of any  business.  At the present the Company has not
identified  any  assets or  business  opportunities  for  acquisition.  The only
activity for 2000 was fees incurred for assistance with regulatory filings.

         The  Company  has no  liquidity  and  no  presently  available  capital
resources,  such as  credit  lines,  guarantees,  etc.  and  should a merger  or
acquisition prove unsuccessful, it is possible that the Company may be dissolved
by the State of Nevada for failing to file reports. Should management decide not
to  further  pursue its  acquisition  activities,  management  may  abandon  its
activities and the shares of the Company would become worthless.

         Based  on  current  economic  and  regulatory  conditions,   Management
believes that it is possible,  if not probable,  for a company like the Company,
without assets or many liabilities,  to negotiate a merger or acquisition with a
viable private company.  The opportunity arises principally  because of the high
legal  and  accounting   fees  and  the  length  of  time  associated  with  the
registration process of "going public".  However, should any of these conditions
change,  it is very possible that there would be little or no economic value for
anyone taking over control of the Company.

ITEM 7.           Financial Statements and Supplementary Data.

         See Item 13.

ITEM 8.           Changes in and Disagreements with Accountants on Accounting
                  and Financial Disclosure.

         Not applicable.


                                        5

<PAGE>



                                    PART III

ITEM 9.           Directors and Executive Officers of the Registrant.

         The following table shows the positions held by the Company's  officers
and  directors.  The directors  were appointed in May, 2000 and will serve until
the  next  annual  meeting  of  the  Company's  stockholders,  and  until  their
successors have been elected and have qualified.  The officers were appointed to
their  positions,  and  continues in such  position,  at the  discretion  of the
directors.

                  Name           Age            Position
         Neil E. Crabtreee       40          President, Director
         Dr. Robert Morrow       71          Secretary / Treasurer / Director

         Neil E. Crabtree has served as President and Chief Executive Officer of
the Company since May, 2000.  From June 1992 to May 2000, Mr. Crabtree served as
Founder and Chief  Operating  Officer for Rocky Point,  a producer of nationally
acclaimed,  holiday-oriented  special events.  From March 1989 to June 1992, Mr.
Crabtree  worked  as a Manager  for  Western  Ford  Chrysler,  a large  Ford and
Chrysler  dealership  in Tooele,  Utah.  From July 1981, to February  1989,  Mr.
Crabtree  worked as a Manager  for  Mister  Lease,  Inc.,  a holding  company of
diverse businesses including retail,  wholesale,  and manufacturing  operations,
where his primary  responsibilities  included new business evaluation,  mergers,
and  acquisitions.  Mr. Crabtree  graduated with a Bachelor of Science degree in
Business  Administration  from Weber State University in June 1997, where he was
named "Outstanding Graduate in Management." Mr. Crabtree received his Masters of
Business  Administration  degree from the University of Utah in May `1999, where
he was named "Outstanding  Graduate,  MBA Class of 1999." Mr. Crabtee is also an
ecclesiastical leader in his community.

         Dr.  Robert  Morrow has for the most  recent five years  continued  his
private practice of orthopedic surgery. Dr. Morrow graduated from the University
of Florida in 1951 with BS degrees in Chemistry, Biology, and Psychology.

ITEM 10.          Executive Compensation

         The  Company  has  made no  arrangements  for the  remuneration  of its
officers  and   directors,   except  that  they  will  be  entitled  to  receive
reimbursement for actual, demonstrable out-of-pocket expenses,  including travel
expenses if any, made on the Company's  behalf in the  investigation of business
opportunities.  No  remuneration  has been  paid to the  Company's  officers  or
directors  prior  to the  filing  of  this  form.  There  are no  agreements  or
understandings  with  respect to the amount or  remuneration  that  officers and
directors  are expected to receive in the future.  Management  takes no salaries
from  the  Company  and  does  not  anticipate  receiving  any  salaries  in the
foreseeable  future. No present  prediction or representation  can be made as to
the  compensation  or other  remuneration  which may  ultimately  be paid to the
Company's  management,  since  upon the  successful  consummation  of a business
opportunity,  substantial  changes may occur in the structure of the Company and
its  management.  At such time,  contracts may be negotiated with new management
requiring the payment of annual  salaries or other forms of  compensation  which
cannot  presently  be  anticipated.  Use of the  term  "new  management"  is not
intended  to  preclude  the  possibility  that any of the  present  officers  or
directors  of the  Company  might be  elected  to  serve in the same or  similar
capacities  upon the Company's  decision to  participate in one or more business
opportunities.

         The Company's management may benefit directly or indirectly by payments
of consulting fees, payment of finders fees to others,  sales of insiders' stock
positions in whole or in part to a private company, the Company or management of
the Company or through the payment of salaries, or any other methods of payments
through which insiders or current investors receive funds,  stock,  other assets
or  anything  of value  whether  tangible  or  intangible.  There  are no plans,
proposals, arrangements or understandings with respect to the sale of additional
securities to affiliates,  current  shareholders or others prior to the location
of a business opportunity.


                                        6

<PAGE>



ITEM 11.         Security Ownership of Certain Beneficial Owners and Management.

         The following  table sets forth,  as of December 31, 2000,  information
regarding the beneficial ownership of shares by each person known by the Company
to own five percent or more of the outstanding  shares, by each of the directors
and by the officers and directors as a group.


<TABLE>
<CAPTION>
                                         Name & address                          Amount of                           Percent
       Title of Class                  of beneficial owner                 beneficial ownership                     of Class
       --------------                  -------------------                 --------------------                     --------
<S>                                    <C>                                        <C>                                <C>
           Common                         Mark Timothy                            229,800                            22.98%
                                           1466 Vintry
                                   Salt Lake City, Utah 84121
           Common                        Ann Timothy (1)                          275,000                            27.50%
                                           1466 Vintry
                                   Salt Lake City, Utah 84121
           Common                         Julie Thorson                           275,000                            27.50%
                                       1963 Stryker Avenue
                                      Park City, Utah 84060
           Common                  Capital General Corporation                    62,208                              6.22%
                                  3098 South Highland Dr. #460
                                   Salt Lake City, Utah 84106
           Common                       Neil E. Crabtree                             0                                0.00%
                                           2601 Quincy
                                        Ogden, Utah 84401
           Common                       Dr. Robert Morrow                            0                                0.00%
                                           2601 Quincy
                                        Ogden, Utah 84401
           Common                  All Officers and Directors                        0                                0.00%
                                           as a group
         (1) Ann Timothy is the mother of Mark Timothy.
</TABLE>

ITEM 12.          Certain Relationships and Related Transactions

         No officer,  director, nominee for election as a director, or associate
of such  officer,  director  or  nominee  is or has been in debt to the  Company
during the last fiscal year.  However,  the Company's officers,  directors,  and
major shareholder,  has made an oral undertaking to make loans to the Company in
amounts sufficient to enable it to satisfy its reporting  requirements and other
obligations  incumbent on it as a public company, and to commence,  on a limited
basis, the process of investigating possible merger and acquisition  candidates.
The Company's  status as a publicly-held  corporation may enhance its ability to
locate  potential  business  ventures.  The loans will be interest  free and are
intended  to be repaid  at a future  date,  if or when the  Company  shall  have
received  sufficient  funds  through  any  business  acquisition.  The loans are
intended to provide for the payment of filing fees,  professional fees, printing
and copying fees and other miscellaneous fees.


                                        7

<PAGE>



                                     PART IV

TEM 13.           Exhibits, Financial Statement Schedules, and Reports on
                  Form 8-K.

         Financial Statements and Financial Statement Schedules.

         Financial Statements - December 31, 2000

         Reports on Form 8-K

         There were no reports on Form 8-K filed  during the fiscal  year ending
December 31, 2000.



                                        8

<PAGE>




                                      Smith
                                        &
                                     Company

           A Professional Corporation of Certified Public Accountants

                          INDEPENDENT AUDITOR'S REPORT


Board of Directors
Rocky Point Pharmaceuticals, Inc. (A Development Stage Company)

We have audited the accompanying balance sheets of Rocky Point  Pharmaceuticals,
Inc. (a Nevada  corporation)  (a  development  stage company) as of December 31,
2000  and  1999,  and  the  related   statements  of   operations,   changes  in
stockholders' (deficit) equity, and cash flows for the years then ended, and for
the period of April 14, 1986 (date of  inception)  to December 31,  2000.  These
financial  statements are the  responsibility of the Company's  management.  Our
responsibility  is to express an opinion on these financial  statements based on
our audits.

We conducted our audits in accordance with auditing standards generally accepted
in the United States. Those standards require that we plan and perform the audit
to obtain reasonable  assurance about whether the financial  statements are free
of material misstatement. An audit includes examining, on a test basis, evidence
supporting  the amounts and  disclosures in the financial  statements.  An audit
also includes assessing the accounting principles used and significant estimates
made by  management,  as well as  evaluating  the  overall  financial  statement
presentation.  We believe  that our audits  provide a  reasonable  basis for our
opinion.

In our opinion,  the financial  statements  referred to above present fairly, in
all material respects,  the financial  position of Rocky Point  Pharmaceuticals,
Inc. (a  development  stage  company) as of December 31, 2000 and 1999,  and the
results of its operations,  changes in stockholders'  (deficit) equity,  and its
cash flows for the years then ended,  and for the period of April 14, 1986 (date
of  inception)  to December 31, 2000 in conformity  with  accounting  principles
generally accepted in the United States.


                                                      /s/ Smith & Company
                                                    CERTIFIED PUBLIC ACCOUNTANTS


Salt Lake City, Utah
February 15, 2001

          10 West 100 South, Suite 700o Salt Lake City, Utah 84101-1554
              Telephone: (801) 575-8297o Facsimile: (801) 575-8306
                       E-mail: smith&co@smithandcocpa.com
          Members: American Institute of Certified Public Accountantso
                Utah Association of Certified Public Accountants

                                        9

<PAGE>



                        Rocky Point Pharmaceuticals, Inc.
                          (A Development Stage Company)
                                 BALANCE SHEETS




<TABLE>
<CAPTION>
                                                                         December 31,
                                                                  2000                  1999
                                                            -----------------     -----------------
             ASSETS
CURRENT ASSETS
<S>                                                         <C>                   <C>
         Cash in bank                                       $               0     $               0
                                                            -----------------     -----------------

                      TOTAL CURRENT ASSETS                                  0                     0

OTHER ASSETS
         Organization costs (Note 1)                                        0                     0
                                                            -----------------     -----------------
                                                                            0                     0
                                                            -----------------     -----------------

                                                            $               0     $               0
                                                            =================     =================

             LIABILITIES & (DEFICIT) EQUITY
CURRENT LIABILITIES
         Accounts payable                                   $             850     $               0
                                                            -----------------     -----------------

                      TOTAL CURRENT LIABILITIES                           850                     0

STOCKHOLDERS' (DEFICIT) EQUITY
         Common Stock $.001 par value:
          Authorized - 100,000,000 shares
          Issued and outstanding 1,000,000 shares                       1,000                 1,000
         Additional paid-in capital                                     1,000                 1,000
         Deficit accumulated during
          the development stage                                        (2,850)               (2,000)
                                                            -----------------     -----------------

                      TOTAL STOCKHOLDERS' (DEFICIT) EQUITY               (850)                    0
                                                            -----------------     -----------------

                                                            $               0     $               0
                                                            =================     =================
</TABLE>

See Notes to Financial Statements.

                                       10

<PAGE>



                        Rocky Point Pharmaceuticals, Inc.
                          (A Development Stage Company)
                            STATEMENTS OF OPERATIONS




<TABLE>
<CAPTION>
                                                                                           4/14/86
                                                              Years ended                 (Date of
                                                              December 31,             inception) to
                                                       2000              1999              12/31/00
                                                     -----------       -----------       -----------
<S>                                                  <C>               <C>               <C>
Net sales                                            $         0       $         0       $         0
Cost of sales                                                  0                 0                 0
                                                     -----------       -----------       -----------

                             GROSS PROFIT                      0                 0                 0


General & administrative
 expenses                                                    850                 0             2,850
                                                     -----------       -----------       -----------

                             NET LOSS                $      (850)      $         0       $    (2,850)
                                                     ===========       ===========       ===========


Basic and Diluted earnings per share
Net income (loss) per weighted average share         $      (.00)      $       .00
                                                     ===========       ===========


Weighted average number of common shares
         used to compute net income (loss) per
         weighted average share                        1,000,000         1,000,000
                                                     ===========       ===========
</TABLE>







See Notes to Financial Statements.

                                       11

<PAGE>



                        Rocky Point Pharmaceuticals, Inc.
                          (A Development Stage Company)
             STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY



<TABLE>
<CAPTION>
                                                                                                  Deficit
                                                                                                Accumulated
                                               Common Stock                 Additional            During
                                             Par Value $0.001                Paid-in            Development
                                         Shares            Amount             Capital              Stage
                                      --------------    --------------    -----------------    --------------
<S>                                   <C>               <C>               <C>                  <C>
Balances at 4/14/86
         (Date of inception)                       0    $            0    $               0    $            0
         Issuance of common
             stock (restricted)
             at $.002 per share
             at 4/14/86                    1,000,000             1,000                1,000
         Net loss for period                                                                           (1,950)
                                      --------------    --------------    -----------------    --------------
Balances at 12/31/86                       1,000,000             1,000                1,000            (1,950)
         Net loss for year                                                                                (10)
                                      --------------    --------------    -----------------    --------------
Balances at 12/31/87                       1,000,000             1,000                1,000            (1,960)
         Net loss for year                                                                                (10)
                                      --------------    --------------    -----------------    --------------
Balances at 12/31/88                       1,000,000             1,000                1,000            (1,970)
         Net loss for year                                                                                (10)
                                      --------------    --------------    -----------------    --------------
Balances at 12/31/89                       1,000,000             1,000                1,000            (1,980)
         Net loss for year                                                                                (10)
                                      --------------    --------------    -----------------    --------------
Balances at 12/31/90                       1,000,000             1,000                1,000            (1,990)
         Net loss for year                                                                                (10)
                                      --------------    --------------    -----------------    --------------
Balances at 12/31/91                       1,000,000             1,000                1,000            (2,000)
         Net income for year                                                                                0
                                      --------------    --------------    -----------------    --------------
Balances at 12/31/92                       1,000,000             1,000                1,000            (2,000)
         Net income for year                                                                                0
                                      --------------    --------------    -----------------    --------------
Balances at 12/31/93                       1,000,000             1,000                1,000            (2,000)
         Net income for year                                                                                0
                                      --------------    --------------    -----------------    --------------
Balances at 12/31/94                       1,000,000             1,000                1,000            (2,000)
         Net income for year                                                                                0
                                      --------------    --------------    -----------------    --------------
Balances at 12/31/95                       1,000,000             1,000                1,000            (2,000)
         Net income for year                                                                                0
                                      --------------    --------------    -----------------    --------------
Balances at 12/31/96                       1,000,000             1,000                1,000            (2,000)
         Net income for year                                                                                0
                                      --------------    --------------    -----------------    --------------
Balances at 12/31/97                       1,000,000             1,000                1,000            (2,000)
         Net income for year                                                                                0
                                      --------------    --------------    -----------------    --------------
Balances at 12/31/98                       1,000,000             1,000                1,000            (2,000)
         Net income for year                                                                                0
                                      --------------    --------------    -----------------    --------------
Balances at 12/31/99                       1,000,000             1,000                1,000            (2,000)
         Net loss for year                                                                               (850)
                                      --------------    --------------    -----------------    --------------

Balances at 12/31/00                       1,000,000    $        1,000    $           1,000    $       (2,850)
                                      ==============    ==============    =================    ==============
</TABLE>




See Notes to Financial Statements.

                                       12

<PAGE>



                        Rocky Point Pharmaceuticals, Inc.
                          (A Development Stage Company)
                            STATEMENTS OF CASH FLOWS




<TABLE>
<CAPTION>
                                                                                                             4/14/86
                                                                                 Years ended                (Date of
                                                                                 December 31,              inception) to
                                                                          2000              1999            12/31/00
                                                                      --------------    --------------    --------------
OPERATING ACTIVITIES
<S>                                                                   <C>               <C>               <C>
         Net income (loss)                                            $         (850)   $            0    $       (2,850)
         Adjustments to reconcile net income (loss) to
          cash used by operating  activities:
             Amortization                                                          0                 0                50
             Changes in accounts payable                                         850                 0               850
                                                                      --------------    --------------    --------------

                          NET CASH USED BY
                      OPERATING ACTIVITIES                                         0                 0            (1,950)

INVESTING ACTIVITIES
         Organization costs                                                        0                 0               (50)
                                                                      --------------    --------------    --------------

                          NET CASH USED BY
                      INVESTING ACTIVITIES                                         0                 0               (50)

FINANCING ACTIVITIES
         Proceeds from sale of  common stock                                       0                 0             2,000
                                                                      --------------    --------------    --------------

                      NET CASH PROVIDED BY
                      FINANCING ACTIVITIES                                         0                 0             2,000
                                                                      --------------    --------------    --------------

                          INCREASE IN CASH
                      AND CASH EQUIVALENTS                                         0                 0                 0

         Cash and cash equivalents at beginning of year                            0                 0                 0
                                                                      --------------    --------------    --------------

                  CASH & CASH EQUIVALENTS
                           AT END OF YEAR                             $            0    $            0    $            0
                                                                      ==============    ==============    ==============
</TABLE>




See Notes to Financial Statements.

                                       13

<PAGE>


                        Rocky Point Pharmaceuticals, Inc.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                                December 31, 2000


NOTE 1:  SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES
         Accounting Methods:
         The Company  recognizes income and expenses based on the accrual method
         of accounting.

         Dividend Policy:
         The  Company  has not yet  adopted  any  policy  regarding  payment  of
         dividends.

         Organization Costs:
         The Company amortized its organization costs over a five year period.

         Cash and Cash Equivalents:
         For  financial  statement  purposes,  the Company  considers all highly
         liquid  investments  with an original  maturity date of three months or
         less when purchased to be cash equivalents.

         Estimates:
         The  preparation of financial  statements in conformity  with generally
         accepted  accounting  principles  requires management to make estimates
         and   assumptions   that  affect  the   reported   amounts  of  assets,
         liabilities,   revenues  and  expenses  during  the  reporting  period.
         Estimates  also  affect  the   disclosure  of  contingent   assets  and
         liabilities  at the date of the financial  statements.  Actual  results
         could differ from these statements.

         Net Loss Per Share:
         Basic and  diluted  loss per share is  computed  by  dividing  net loss
         available  to common  shareholders  by the weighted  average  number of
         common shares outstanding during the periods presented.

         Income Taxes:
         The Company  records the income tax effect of  transactions in the same
         year that the  transactions  enter  into the  determination  of income,
         regardless of when the  transactions  are  recognized for tax purposes.
         Tax credits are  recorded in the year  realized.  Since the Company has
         not yet realized income as of the date of this report, no provision for
         income taxes has been made.

         In February,  1992, the Financial  Accounting  Standards  Board adopted
         Statement of Financial  Accounting  Standards No. 109,  Accounting  for
         Income Taxes, which supersedes substantially all existing authoritative
         literature for  accounting  for income taxes and requires  deferred tax
         balances  to be  adjusted to reflect the tax rates in effect when those
         amounts are expected to become payable or refundable. The Statement was
         applied in the  Company's  financial  statements  for the  fiscal  year
         commencing January 1, 1993.

         At  December  31,  2000 a deferred  tax asset of about  $1,000 has been
         fully  reserved  due to the  Company's  lack of  operations  to provide
         income to use the net operating  loss carryover of $2,850 which expires
         as follows:

                  Year Ended                Expires                   Amount
               -----------------       -----------------           -------------
               December 31, 1986       December 31, 2001           $       1,950
               December 31, 1987       December 31, 2002                      10
               December 31, 1988       December 31, 2003                      10
               December 31, 1989       December 31, 2004                      10
               December 31, 1990       December 31, 2005                      10
               December 31, 1991       December 31, 2006                      10
               December 31, 2000       December 31, 2020                     850
                                                                   -------------
                                                                   $       2,850
                                                                   =============

NOTE 2:  DEVELOPMENT STAGE COMPANY
         The Company was  incorporated  as Upsilon,  Inc.  under the laws of the
         State of Utah on April 14, 1986 and has been in the  development  stage
         since incorporation. On December 30, 1993, the Company was dissolved as
         a Utah corporation and reincorporated in Nevada as Upsilon  Industries,
         Inc. On July 21,  1995,  the Company  changed its name to TTN  Capitol,
         Inc.,  on October 15,  1995,  the  Company  changed its name to Wasatch
         Pharmaceutical,  Inc., and on May 31, 2000 the Company changed its name
         to Rocky Point Pharmaceuticals, Inc.

NOTE 3:  CAPITALIZATION
         On the date of incorporation,  the Company sold 1,000,000 shares of its
         common stock to Capital  General  Corporation  for $2,000 cash,  for an
         average  consideration  of $.002 per share.  The  Company's  authorized
         stock includes 100,000,000 shares of common stock at $.001 par value.

                                       14

<PAGE>



                        Rocky Point Pharmaceuticals, Inc.
                          (A Development Stage Company)
                    NOTES TO FINANCIAL STATEMENTS (continued)
                                December 31, 2000



NOTE 4:  RELATED PARTY TRANSACTIONS
         The Company neither owns nor leases any real property.  Office services
         are provided,  without charge, by an officer. Such costs are immaterial
         to the financial statements, and, accordingly,  have not been reflected
         therein.  The  officers  and  directors  of the Company are involved in
         other business  activities and may, in the future,  become  involved in
         other  business  opportunities.  If  a  specific  business  opportunity
         becomes  available,  such  persons  may face a  conflict  in  selecting
         between the Company and their other business interests. The Company has
         not formulated a policy for the resolution of such conflicts.

                                       15

<PAGE>


                                   SIGNATURES

         Pursuant to the  requirements  of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.

                                    Rocky Point Pharmaceuticals, Inc.



Dated: March 26, 2001               By:     /s/ Neil E. Crabtree
       --------------                  -----------------------------------------
                                    Neil E. Crabtree, President and Director

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
this  report has been  signed  below by the  following  persons on behalf of the
registrant and in the capacities and on the dates indicated.



Dated: March 26, 2001               By:     /s/ Neil E. Crabtree
      ---------------                  -----------------------------------------
                                    Neil E. Crabtree, President and Director



Dated: March 26, 2001               By:     /s/ Dr. Robert Morrow
      ---------------                  -----------------------------------------
                                    Dr. Robert Morrow, Secretary / Treasurer
                                                       and Director



                                       16